Nektar Therapeutics
Ownership
Ownership Structure
Who owns Nektar Therapeutics (NKTR)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 82.8% of the shares are freely tradable; institutional investors hold 92.1%.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| FMR Inc | 14.84 | 5,067,920 | +17.8 | 06/30/2026 |
| BlackRock Inc | 8.62 | 2,941,851 | +324.7 | 06/30/2026 |
| Bvf Inc | 7.00 | 2,391,075 | -6.6 | 06/30/2026 |
| Vanguard Capital Management, LLC | 4.38 | 1,496,849 | +25.0 | 06/30/2026 |
| Two Sigma Investments LLC | 3.52 | 1,202,004 | +29.1 | 06/30/2026 |
| Vestal Point Capital LP | 2.93 | 1,000,000 | +250.9 | 06/30/2026 |
| Morgan Stanley - Brokerage Accounts | 2.74 | 936,560 | +42.0 | 06/30/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Fidelity Growth Company Fund | 5.42 | 1,850,478 | +1.0 | 08/31/2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 3.17 | 1,081,579 | +0.3 | 09/30/2026 |
| State Street® SPDR® S&P® Biotech ETF | 3.07 | 1,046,474 | +2.7 | 10/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider holdings
| Person | Role | Shares | Value | As of | Type |
|---|---|---|---|---|---|
| Robin Howard W | President & CEO | 54,627 | 2,097,677 $ | Aug 18, 2026 | direct |
| Greer R Scott | Director | 22,239 | 853,978 $ | Sep 23, 2026 | direct |
| Chess Robert | Director | 19,019 | 730,330 $ | Sep 23, 2026 | direct |
| Whitfield Roy A | Director | 16,417 | 630,413 $ | Sep 23, 2026 | direct |
| Zalevsky Jonathan | Chief R&D Officer | 9,570 | 367,488 $ | Aug 18, 2026 | direct |
| Ajer Jeffrey Robert | Director | 4,277 | 164,237 $ | Sep 23, 2026 | direct |
| Brainard Diana | Director | 3,904 | 149,914 $ | Sep 23, 2026 | direct |
Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.
Insiders
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 23, 2026 | Whitfield Roy A | Director | Other | 2,000 | 0.00 | – |
| Sep 23, 2026 | Greer R Scott | Director | Other | 2,000 | 0.00 | – |
| Sep 23, 2026 | Chess Robert | Director | Other | 2,000 | 0.00 | – |
| Sep 23, 2026 | Brainard Diana | Director | Other | 2,000 | 0.00 | – |
| Sep 23, 2026 | Ajer Jeffrey Robert | Director | Other | 2,000 | 0.00 | – |
| Aug 18, 2026 | Zalevsky Jonathan | Chief R&D Officer | Sell | 186 | 71.98 | 13,388 |
| Aug 18, 2026 | Robin Howard W | President & CEO | Sell | 418 | 71.98 | 30,088 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →
Data as of: November 11, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.